Page 36 - Read Online

Page 8 of 9 Yoo et al. Hepatoma Res 2020;6:9 I http://dx.doi.org/10.20517/2394-5079.2019.49

DECLARATIONS
Authors’ contributions
Study concept and design: Yoo SH, Kwon JH
Acquisition of data: Yoo SH
Drafting of the manuscript: Yoo SH
Study supervision: Kwon JH

Availability of data and materials
Not applicable.

Financial support and sponsorship
None.

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2020.

REFERENCES
1. Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018
practice guidance by the American association for the study of liver diseases. Hepatology 2018;68:723-50.
2. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, et al. Peginterferon alfa-2b plus ribavirin compared with interferon
alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65.
3. Zeuzem S, Hultcrantz R, Bourliere M, Goeser T, Marcellin P, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic
hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004;40:993-9.
4. Lee SD, Yu ML, Cheng PN, Lai MY, Chao YC, et al. Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and
interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan. J Viral Hepat 2005;12:283-91.
5. Morgan TR, Ghany MG, Kim HY, Snow KK, Shiffman ML, et al; Group H-CT. Outcome of sustained virological responders with
histologically advanced chronic hepatitis C. Hepatology 2010;52:833-44.
6. Lok AS, Everhart JE, Wright EC, Di Bisceglie AM, Kim HY, et al; Group H-CT. Maintenance peginterferon therapy and other factors
associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology 2011;140:840-9.
7. van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, et al. Association between sustained virological response and all-cause
mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012;308:2584-93.
8. Kowdley KV, Lawitz E, Poordad F, Cohen DE, Nelson DR, et al. Phase 2b trial of interferon-free therapy for hepatitis C virus
genotype 1. N Engl J Med 2014;370:222-32.
9. Lawitz E, Poordad FF, Pang PS, Hyland RH, Ding X, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without
ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label,
randomised, phase 2 trial. Lancet 2014;383:515-23.
10. Muir AJ, Poordad F, Lalezari J, Everson G, Dore GJ, et al. Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C
virus genotype 1 infection with compensated cirrhosis. JAMA 2015;313:1736-44.
11. Lawitz E, Makara M, Akarca US, Thuluvath PJ, Preotescu LL, et al. Efficacy and safety of ombitasvir, paritaprevir, and ritonavir
in an open-label study of patients with genotype 1b chronic hepatitis C virus infection with and without cirrhosis. Gastroenterology
2015;149:971-80.e1.
12. Kwon JH, Yoo SH, Nam SW, Kim HY, Kim CW, et al. Clinical outcomes after the introduction of direct antiviral agents for patients
infected with genotype 1b hepatitis C virus depending on the regimens: A multicenter study in Korea. J Med Virol 2019;91:1104-11.
13. Reig M, Marino Z, Perello C, Inarrairaegui M, Ribeiro A, et al. Unexpected high rate of early tumor recurrence in patients with HCV-
related HCC undergoing interferon-free therapy. J Hepatol 2016;65:719-26.
14. Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-